Understand the source comparison
Best Peptides for Cutting Cycles: Evidence Comparison
CJC-1295 + Ipamorelin GH secretagogue (GHRH analog + ghrelin mimetic) Phase 2 trials showing 4.2% FFM increase, 7.8% VAT reduction over 12 weeks 100–300mcg ipamorelin + 100–200mcg CJC-1295, 2–3× weekly Mild: injection-site reaction, transient water retention,
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295 + Ipamorelin
- GH secretagogue (GHRH analog + ghrelin mimetic)
- Phase 2 trials showing 4.2% FFM increase, 7.8% VAT reduction over 12 weeks
- 100–300mcg ipamorelin + 100–200mcg CJC-1295, 2–3× weekly
- Mild: injection-site reaction, transient water retention, rare flushing
- Most evidence-backed dual-action compound for body recomposition
- AOD-9604
- GH fragment targeting lipolysis without GH receptor binding
- Monash University RCT: 12.6% abdominal fat reduction, 300 participants, 12 weeks
- 1mg daily SC injection
- Minimal: mild injection-site irritation, no glucose or IGF-1 impact
- Best isolated lipolytic effect without systemic GH side effects
- Tesofensine
- Triple reuptake inhibitor (dopamine, norepinephrine, serotonin)
- Phase 3 trial: 10.6% body weight reduction vs 1.8% placebo over 24 weeks
- 0.25–0.5mg daily oral
- Moderate: CNS stimulation, dry mouth, insomnia at >0.5mg
- Highest absolute fat loss but requires CNS tolerance assessment
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic increasing GH and IGF-1
- Multiple trials showing 8–12% FFM increase, appetite stimulation complicates cutting use
- 12.5–25mg daily oral
- Significant: increased appetite (counterproductive in deficit), water retention, insulin resistance risk
- Effective GH elevation but appetite increase limits cutting-phase utility
- GLP-1 agonists (semaglutide, tirzepatide)
- Appetite suppression via delayed gastric emptying
- Extensive Phase 3 data: 15–22% body weight reduction, primarily through caloric restriction
- 2.5–15mg weekly SC (tirzepatide range)
- GI: nausea, vomiting during titration; rare pancreatitis
- Appetite control excellent but no direct lipolytic mechanism